

Collaborative Working

Executive Summary

Project title:	Atrial Fibrillation (AF) Detection in Community Pharmacy
Project partners:	O'Brien's Pharmacy and Daiichi Sankyo UK Ltd
Start date:	December 2021- June 2022
Project Support:	Daiichi Sankyo UK Ltd direct contribution £25,275 O'Brien's Pharmacy indirect contribution £23,962

Project summary

The overall aim is to increase AF detection rates, initiate appropriate therapy after confirmed diagnosis (via referral to the patients GP) and thus reduce the burden on the NHS. In this project O'Brien's a Community Pharmacy Group (which consist of nine outlets) based in North West England will identify suspected AF patients in conjunction with an already existing NHS health check service via symptoms, pulse, or device. Where AF is suspected the Pharmacist would then make a referral to the patients GP.

Expected benefits to patients the Organisation & Daiichi Sankyo UK Ltd

Expected benefits for the patients:

- Aid the patient for easily accessible symptom check to gauge if they are showing symptoms of AF.
 - Ensure timely diagnosis and treatment
 - Dedicates time for patients to be correctly counselled and educated
 - Aid in stroke prevention by appropriate detection
 - Improve symptom control and quality of life

Expected benefits for the Organisation:

- This project aligns to the 5-year plan in enhancing patient care, and the wellbeing of the community.
- The overall benefit is early indication of AF will reduce the risk to the patient of stroke, and ultimately the costs associated with this to the NHS
- Increased footfall into O'Brien's outlets
- Increased reputational value

Expected benefits for Daiichi Sankyo UK Ltd:

- Improve management and treatment of patients with atrial fibrillation by working in partnership with Community Pharmacy.

- Improve Daiichi Sankyo's reputational profile amongst local and national stakeholders and expand its collaborative portfolio.
- Create more opportunities for the appropriate use of Direct Oral Anticoagulants, including Daiichi Sankyo UK's medicines in appropriate patients in line with local treatment guidelines. If this improvement occurs, we are likely to see an increase in DOAC prescriptions.
- Journal publication and associated publicity likely resulting in future collaborations and subsequent rise in profile of Daiichi Sankyo UK Ltd.